

**BAFNA PHARMACEUTICALS LIMITED ( CIN L24294TN1995PLC030698)**

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Unaudited Standalone Financial Results for the Quarter and Nine Months Ended 31st December 2018

PART I

(Rs. In Lakhs) except EPS

Sl.No	Particulars	3 months ended	3 months ended	Corresponding	Year to date	Year to date	For the Previous
		(31-12-2018)	(30-09-2018)	3 months ended (31-12-2017)	Upto 31.12.2018	Upto 31.12.2017	Year ended (31.03.2018)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue From operations	1,307.49	883.79	1,086.24	3,386.40	3,064.79	4,717.07
II	Other Income	31.01	(3.47)	21.91	36.73	29.32	122.80
II(a)	Profit on sale of Investment			3,003.64	-	3,003.64	3,003.64
III	<b>Total Income (I+II)</b>	<b>1,338.50</b>	<b>880.32</b>	<b>4,111.80</b>	<b>3,423.13</b>	<b>6,097.75</b>	<b>7,843.51</b>
IV	<b>EXPENSES</b>						
a)	Cost of materials consumed	961.26	532.33	515.08	2,587.39	1,389.14	2,680.07
b)	Purchases of Stock-in-Trade	(0.00)	15.68	253.67	30.68	698.51	1,298.95
c)	goods, Stock-in -Trade and work-in-progress	(70.19)	17.16	1.20	(58.10)	453.65	409.20
d)	Employee benefits expense	221.99	217.92	182.48	634.21	519.00	747.49
e)	Finance costs	46.35	61.92	173.33	191.48	578.33	680.53
f)	Depreciation and amortization	90.22	75.24	98.71	265.45	287.90	364.59
g)	Other expenses	77.21	82.38	78.06	238.15	228.86	3,090.24
	<b>Total expenses (IV)</b>	<b>1,326.83</b>	<b>1,002.63</b>	<b>1,302.53</b>	<b>3,889.28</b>	<b>4,155.39</b>	<b>9,271.08</b>
V	<b>Profit/(loss) before exceptional Items</b>	<b>11.67</b>	<b>(122.32)</b>	<b>2,809.27</b>	<b>(466.15)</b>	<b>1,942.36</b>	<b>(1,427.56)</b>
VI	Exceptional Items						
VII	<b>Profit/ (loss) before exceptions Items</b>	<b>11.67</b>	<b>(122.32)</b>	<b>2,809.27</b>	<b>(466.15)</b>	<b>1,942.36</b>	<b>(1,427.56)</b>
VIII	Tax expense:						
	(1) Current tax			-			
	(2) Deferred tax	(0.43)	5.33	-	0.71	170.73	217.52
IX	<b>Profit (Loss) for the period from</b>	<b>12.10</b>	<b>(127.64)</b>	<b>2,809.27</b>	<b>(466.85)</b>	<b>1,771.64</b>	<b>(1,645.09)</b>
X	Profit/(loss) from discontinued			-			
XI	Tax expenses of discontinued			-			
XII	<b>Profit/(loss) from Discontinued operations (after tax) (X-XI)</b>			-			
XIII	<b>Profit/(loss) for the period (IX+XII)</b>	<b>12.10</b>	<b>(127.64)</b>	<b>2,809.27</b>	<b>(466.85)</b>	<b>1,771.64</b>	<b>(1,645.09)</b>
XIV	<b>Other Comprehensive Income</b>						
	A. (i) Items that will not be reclassified	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to	-	-	-	-	-	-
	(ii) Income tax relating to items that	-	-	-	-	-	-
XV	<b>period (XIII+XIV)Comprising Profit (Loss) and Other comprehensive Income for the period )</b>	<b>12.10</b>	<b>(127.64)</b>	<b>2,809.27</b>	<b>(466.85)</b>	<b>1,771.64</b>	<b>(1,645.09)</b>
XVI	<b>Earnings per equity share (for</b>						
	(1) Basic	0.05	(0.54)	11.88	(1.97)	9.50	(6.95)
	(2) Diluted	0.05	(0.54)	11.88	(1.97)	9.50	(6.95)
XVII	<b>Earnings per equity share (for</b>						
	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
XVIII	<b>Earning per equity share (for discontinued &amp; continuing operation)</b>						
	(1)Basic	0.05	(0.54)	11.88	(1.97)	9.50	(6.95)
	(2) Diluted	0.05	(0.54)	11.88	(1.97)	9.50	(6.95)

- The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 08.02.2019
- The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.
- The above figures have been regrouped and Re-arranged Wherever considered necessary
- The figures of the Quarter are the balancing figures in respect of the Financial year and the published year to date figures upto the Third quarter of the Financial year.

Place: Chennai  
Date: 08.02.2019



For BAFNA PHARMACEUTICALS LIMITED

*(Signature)*  
( BAFNA MAHAVEER CHAND)  
MANAGING DIRECTOR  
DIN:01458211